TNF␣-induced cardioprotection is independent of the activation of the prosurvival kinase Erk
However, the signalling pathways involved in the cardioprotective effect of TNF␣ remain poorly understood. Similar to ischaemic preconditioning, the protective effect of TNF␣ occurs via the sphingolipids, (6) generation of free radicals, (6, 8) the activation of the signal transducer and activator of transcription-3 (STAT-3) (9) and the phosphorylation of Bcl-2 antagonist of cell death (BAD). (9) While ischaemic preconditioning has been shown to confer cardio-protection via the activation of the prosurvival
INTRODUCTION
Cellular protection of the heart is the new therapeutic challenge following successes achieved with reperfusion therapy. (1, 2) A powerful biological phenomenon that is being scientifi cally exploited to dissect out cell survival programs is known as ischaemic preconditioning. (3) Ischaemic preconditioning is evoked by sublethal transient ischaemia that paradoxically results in increased tolerance against subsequent lethal ischaemia. Identifi cation of cell survival programs activated by preconditioning may identify new therapeutic targets for future drug development to promote cell survival in the heart.
Tumour Necrosis Factor alpha (TNF␣) is a pleiotropic cytokine that has been implicated to play a role in cellular infl ammation, growth, apoptosis but also cell survival. (4) We have previously reported that ischaemic preconditioning evokes an upregulation of cardiac steady-state TNF␣ peptide levels in the mouse heart and a loss of protection was associated with ischaemic preconditioning in TNF␣ defi cient mice. (5) In addition, we have demonstrated that TNF␣ could mimic ischaemic preconditioning in a dose and time-dependent manner in the rat heart. protect independently of the activation of Akt. (9, 11) The necessity for the activation of the prosurvival kinase extracellular signalregulated kinase (Erk) during the ischaemic preconditioning stimulus has led to confl icting data in the literature. (12, 13) However, this prosurvival kinase has never been studied during a TNF␣ preconditioning stimulus.
Therefore, using an isolated rat heart model, the aim of this study is to investigate whether both ischaemic preconditioning-and TNF␣-induced cardio-protection require the activation of Erk during the preconditioning stimulus also called the trigger phase.
METHODS

Animal groups
All the experiments were conducted on adult male Long-Evans The perfusion protocol is shown in Figure 1 . All hearts were allowed to equilibrate for 15 min and were consequently subjected to a standard 30 min regional ischaemia (induced by tightening a snare around the left coronary artery) followed by 120 min of reperfusion. Ischaemic preconditioning (IPC) was performed by 2 cycles of 5 min global ischaemia-reperfusion prior to the standard ischaemia. TNF␣ (0.5ng/ml) was given for 7 min followed by a 10 min of wash out period before the standard ischaemia.
Additional groups were perfused with the MAPK/Erk 1/2 kinase (MEK 1/2) inhibitor PD 98059 (10μM) for 15 min followed by 5 min washout prior to the ischaemia-reperfusion insult.
For infarct size measurement, the coronary artery was reoccluded at the end of the reperfusion period and a solution of 2.5% Evans Blue was perfused to delineate the area at risk.
Hearts were then frozen and cut into slices, incubated in sodium phosphate buffer containing 1% w/v triphenyltetrazolium chloride (TTC) for 15 min to visualise the unstained infarcted region.
Infarct and risk zone areas were determined with planimetry and infarct was expressed as a percentage of the risk zone.
Western blot analysis
Hearts from control or preconditioned rat hearts were collected prior to the 30 min of regional ischaemia. The ventricular tissue was excised and freeze-clamped in liquid nitrogen before being stored at -80C. Cytosolic proteins were extracted as previously published. 
Pharmacologic agents
Recombinant rat tumour necrosis factor alpha was obtained from Pepro Tech EC Ltd (London, UK). All the chemicals were obtained from Sigma Chemical Company (St Louis, MO, USA).
Statistical analysis
Data are presented as mean ± SEM (n≥6). Comparisons between multiple groups were performed by one-way ANOVA followed by the Student-Newman-Keul post hoc test (Graph Pad Instat).
A value of p<0.05 was considered statistically signifi cant.
RESULTS
PD 98059 does not infl uence the infarct size in ischaemic or
TNF␣ preconditioning.
To investigate the role of Erk 1/2, we measured infarct size as the percentage of the area at risk in hearts perfused with an inhibitor of MEK 1/2 (PD 98059). Ischaemic control hearts had an area at risk of 46.4±1.5% and an infarct size of 28.4±3.7%
( Figure 2 ). The size of the infarct confi rms previous data from our laboratory. (6, 9, 14) Although the area at risk did not differ amongst the different groups (data not shown), both IPC and pharmacological preconditioning with TNF␣ reduced the infarct size compared with the ischaemic control group (3.2±1.6 and 6.6±2.0% respectively; p<0.001 vs. ischaemic control group).
When PD98059 was given during the preconditioning stimulus, the protective effects of neither IPC nor TNF␣ were abrogated (3.9±1.4 and 10.6±3.4% respectively; p<0.001 vs. ischaemic control group). Of note, PD98059, given on its own, did not affect the infarct size compared with the ischaemic control group (30.5±4.0%, ns vs. ischaemic control group).
IPC but not TNF␣ activates phosphorylation of Erk 1/2 during the preconditioning stimulus.
We explored whether Erk was phosphorylated following the preconditioning stimulus with ischaemia or with TNF␣. As shown in 
DISCUSSION
Using the isolated rat heart model, our novel data show -for the fi rst time -that TNF␣ mimics ischaemic preconditioning independently of the activation of the prosurvival kinase Erk 1/2 prior to the ischaemic insult. In addition, we report that ischaemic preconditioning is associated with an increased phosphorylation of Erk 1/2 prior to the index ischaemia but its inhibition does not abrogate the protection afforded by ischaemic preconditioning.
Previous studies have explored the role of Erk in ischaemic preconditioning but the results have led to confl icting data.
Using an in vivo model of ischaemia/reperfusion in rats, Fryer et al. reported an increased phosphorylation of Erk following a preconditioning stimulus with either ischaemia or an opioid receptor agonist. (15) In addition, inhibition with PD 98059 abolished the cardio-protective effect of both preconditioning stimuli. Similarly, inhibition of Erk with PD 98059 could abolish the ischaemic preconditioning effect in the porcine heart in vivo. (16) In contrast, Behrends et al. failed to fi nd any correlation between Erk phosphorylation and the protection afforded by ischaemic preconditioning. (17) In the isolated rat heart model,
Mocanu et al. demonstrated that Erk phosphorylation occurred
as a result of ischaemic preconditioning but was not required for protection. (13) Using different doses of PD 98059 to inhibit the phosphorylation of Erk they also confi rm that their fi ndings were not dependent on the concentration of the inhibitor used in their model. Using the same model with a different strain of rats, our data correlated with Mocanu's fi ndings, thus suggesting that the discrepancies described in the literature may be related to the different species and models used.
In ischaemic preconditioning (18) and with numerous pharmacological agents (19) (20) (21) the phosphorylation of this kinase is required at the onset of reperfusion as part of the activation of the Reperfusion Injury Salvage Kinase pathway (RISK). However, we were surprised to report that pharmacological preconditioning with TNF␣ protects independently of the phosphorylation of Erk at the time of reperfusion. (9) In addition, its inhibition during the reperfusion phase did not alter the protection afforded by the TNF␣ stimulus. (9) If we had previously shown that Erk is not a mediator in TNF␣-induced preconditioning our present data strongly suggest that Erk does not act as a trigger either. In cardiomyocytes, previous reports have described a phosphorylation of Erk following TNF␣ exposure but the cells were exposed to higher and harmful doses of TNF␣. (22, 23) In addition, the activation of Erk in the cardiomyocytes exposed to 10ng/ml of TNF␣ (dose 20 times higher than the dose used in our model) was so low that it was undetectable with a classic Western blot technique. (23) It is appropriate to suggest that a very small phosphorylation of Erk may have occurred in our model but its inhibition with PD 98059 did not alter the cardio-protective effect of TNF␣, therefore suggesting that Erk is not required for TNF␣ to promote cardio-protection. However, it is important to acknowledge that the use of non specifi c pharmacological inhibitors such as PD 98059 is a limitation to our study. Unfortunately, there is no inhibitor specifi cally targeting the kinase Erk and further studies, using either genetically modifi ed mice such as Erk null mice or siRNA techniques, should be considered to confi rm our fi ndings.
The signalling cascade leading to cardio-protection with TNF␣ still remains poorly understood. Tanno et al. reported that TNF␣-induced protection of the murine heart is independent of p38-MAPK activation. (24) We have shown that the activation of sphingolipids, protein kinase C, the mitochondrial potassium ATP-dependent and reactive oxygen species were required during the preconditioning phase for TNF␣ to confer cardioprotection. (6, 8) The mitochondrial permeability transition pore and the calcium-activated potassium channel have also been suggested. (25) Most importantly, we have recently demonstrated that the activation of STAT-3, as part of the Survivor Activating Factor Enhancement (SAFE) pathway, is a novel and alternative protective pathway that is activated during the trigger phase in both ischaemic preconditioning and pharmacological preconditioning with TNF␣. (26, 27) In conclusion, our present data demonstrate that both ischaemic preconditioning and TNF␣ can confer protection against ischaemiareperfusion, independently of the activation of the prosurvival kinase Erk prior to ischaemia. Combined with our already published work, these data add proof that multiple and independent protective paths can be activated within the heart and that these pathways do not need to be all activated to protect the cells from dying. However, additional work is needed to understand whether activation of several pathways at the same time can confer an additive effect to maximise the protection or if the threshold of protection is already achieved by activation of a single path. ISCHAEMIC PRECONDITIONING
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